Magali Taiel, Chief Medical Officer, will participate to the Mitochondria-Targeted Drug Development Summit to be held virtually from April 27 to 29, 2021.
Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase
Day 2: Thursday April 29, 2021
Time: 9AM – 5PM EST | 3PM – 11PM CEST
Oral presentation: Deep Dive into Gene Therapy & Editing when Targeting Mitochondria
Day 2: Thursday April 29, 2021
Time: 2.4 PM EST | 8.45PM CEST
Title: Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON)
- Examine LHON and its main clinical aspects
- Delve into late-stage development of Lumevoq Gene Therapy
- Discuss regulatory pathways
- Outline key learnings of Lumevoq gene therapy